Payment overview · 2025
General Payments
$989.59
36 reported records · 14 companies
Healthcare provider profile · identity verified
Michael J Sineway, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAWRENCEVILLE, GA · NPI 1962488080
Verified facts
What the public records show
CMS Open Payments records show Michael J Sineway, MD received $989.59 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $167.70 | 16.9% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $139.32 | 14.1% | 5 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $99.95 | 10.1% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $95.79 | 9.7% | 3 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $87.12 | 8.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.23 | 7.8% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $75.29 | 7.6% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $58.75 | 5.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.37 | 5.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.63 | 4.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.02 | 3.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.58 | 2.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.71 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.13 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $889.64 | 35 |
| Education | $99.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $335.06 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $118.71 | 1 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $87.12 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $75.29 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $58.75 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.73 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.37 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.63 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.02 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.14 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 298 | 152 |
| Famotidine | Famotidine | 297 | 137 |
| Metformin Hcl | Metformin Hcl | 188 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 156 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 148 | 52 |
| Omeprazole | Omeprazole | 148 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 124 | 48 |
| Alprazolam | Alprazolam | 120 | 32 |
| Glimepiride | Glimepiride | 113 | 46 |
| Ezetimibe | Ezetimibe | 108 | 40 |
| Gabapentin | Gabapentin | 96 | 38 |
| Terazosin Hcl | Terazosin Hcl | 93 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 32 |
| Tramadol Hcl | Tramadol Hcl | 81 | 18 |
| Potassium Chloride | Potassium Chloride | 78 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 74 | 35 |
| Lisinopril | Lisinopril | 71 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 24 |
| Losartan Potassium | Losartan Potassium | 65 | 25 |
| Furosemide | Furosemide | 62 | 22 |
| Clonazepam | Clonazepam | 58 | 13 |
| Simvastatin | Simvastatin | 58 | 12 |
| Eliquis | Apixaban | 56 | 15 |
| Carvedilol | Carvedilol | 53 | 22 |
| Sertraline Hcl | Sertraline Hcl | 51 | 17 |
| Allopurinol | Allopurinol | 50 | 23 |
| Theophylline Er | Theophylline Anhydrous | 50 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 15 |
| Mounjaro | Tirzepatide | 43 | 11 |
| Torsemide | Torsemide | 43 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 41 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 15 |
| Spironolactone | Spironolactone | 38 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | 16 |
| Azithromycin | Azithromycin | 36 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Prednisone | Prednisone | 33 | 20 |
| Repatha Sureclick | Evolocumab | 33 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | 14 |
| Glipizide | Glipizide | 32 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 30 | 12 |
| Finasteride | Finasteride | 29 | suppressed |
| Meloxicam | Meloxicam | 29 | 15 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | 11 |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Glyburide | Glyburide | 26 | 11 |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 21 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 12 |
| Lovastatin | Lovastatin | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 11 |
| Repaglinide | Repaglinide | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Alprazolam Odt | Alprazolam | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $989.59 · 36 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Cologuard Collection Kit, DUPIXENT, JARDIANCE, Kerendia, LUNA, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, Veozah, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error